Zhejiang Cancer Institute, Zhejiang Cancer Hospital, No. 1 Banshan East Rd., Gongshu District, Hangzhou, Zhejiang 310022, China; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310018, China; The Second Clinical Medical College of Zhejiang Chinese Medicine University, Hangzhou 310053, People's Republic of China.
Zhejiang Cancer Institute, Zhejiang Cancer Hospital, No. 1 Banshan East Rd., Gongshu District, Hangzhou, Zhejiang 310022, China; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310018, China.
Clin Chim Acta. 2025 Jan 15;565:119981. doi: 10.1016/j.cca.2024.119981. Epub 2024 Oct 4.
MUC16/CA125 is a common diagnostic marker for many types of cancer. However, due to the widespread expression of MUC16 in cancer, its specificity and sensitivity as a target are poor, which severely limits its clinical application. In recent years, various studies have shown that the clinical application potential of MUC16/CA125 has been greatly improved. The update of detection technology improves the accuracy and range of detection, and improves the early diagnosis rate of cancer. Targeting MUC16/CA125 is an important strategy for tumor therapy. Targeting residual amino acids, n-glycoylation structures or other targets on the surface of MUC16 cells can greatly improve the accuracy of detection and therapy. The new drug delivery method broke through the original technical shackles, targeted MUC16 positive cells more specifically and improved the drug efficacy. In this paper, the technological advances in detecting and identifying MUC16 targets and the great progress in cancer screening and treatment based on MUC16 as a target are described in detail, revealing the great potential of MUC16 as a target in cancer screening and treatment, and illustrating the potential clinical application value of MUC16.
MUC16/CA125 是多种癌症的常见诊断标志物。然而，由于 MUC16 在癌症中的广泛表达，其作为靶点的特异性和敏感性较差，严重限制了其临床应用。近年来，多项研究表明，MUC16/CA125 的临床应用潜力得到了极大的提高。检测技术的更新提高了检测的准确性和范围，提高了癌症的早期诊断率。针对 MUC16/CA125 是肿瘤治疗的重要策略。针对 MUC16 细胞表面的残留氨基酸、n-糖基化结构或其他靶点，可以大大提高检测和治疗的准确性。新的药物输送方法突破了原有的技术束缚，更特异性地靶向 MUC16 阳性细胞，提高了药物疗效。本文详细描述了检测和鉴定 MUC16 靶点的技术进展，以及基于 MUC16 作为靶点在癌症筛查和治疗方面取得的重大进展，揭示了 MUC16 作为癌症筛查和治疗靶点的巨大潜力，并说明了 MUC16 的潜在临床应用价值。
